ImmunoCellular taps Andrew Gengos to serve as president

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it here each Friday.

ImmunoCellular taps Andrew Gengos to serve as president

ImmunoCellular Therapeutics ($IMUC) called upon Andrew Gengos to serve as president and CEO, and to sit on the board of directors. Gengos most recently held the same positions at Neuraltus Pharmaceuticals. He brings more than 20 years of experience in the life science industry, having held executive leadership positions in both large and emerging companies. As president and CEO of Neuraltus, Gengos implemented the company's clinical, regulatory, fundraising and business development strategies while operating the company on a virtual business model. He also served more than 7 years with Amgen ($AMGN), managing the company's worldwide in-and-outbound business development activities. Release

Andrew Gengos--ImmunoCellular
Gengos will serve as president and CEO.

Alex Gorsky--Johnson & Johnson
Gorksy will serve as chairman of the board of directors.

Namal Nawana--DePuy Synthes Spine
Nawana resigned as president.


> PhaseBio Pharmaceuticals is bringing on Jonathan P. Mow as chief business officer. Mow comes from Amylin Pharmaceuticals, where he implemented the strategy that resulted in Amylin's $7 billion acquisition by Bristol-Myers Squibb ($BMY). Release

> PDL BioPharma ($PDLI) Vice President and CFO Bruce Tomlinson resigned his position due to personal reasons. Release

> Pfenex welcomed Kristi Sarno as a director of business development. Sarno held the position of director of business development at Laureate Biopharma. Release

> Perrigo ($PRGO) called upon Douglas Boothe to serve as executive vice president and general manager of Perrigo Pharmaceuticals, effective in January. Boothe served as CEO of Actavis. Release

> Sorbent Therapeutics landed Jason Levin as chief business officer. Levin worked in the same spot at BrainCells. Release

> Pressure BioSciences announced that Conrad F. Mir joined the company as CFO. Mir was most recently chairman and CEO of Genetic Immunity. Release

> Alliqua named David Johnson to the company's board of directors, as well as executive chairman of Aquamed Technologies, a subsidiary of Alliqua. Johnson recently served as CEO of ConvaTec Inc., after orchestrating the sale of the former ConvaTec division of Bristol-Myers Squibb to Avista Capital Partners and Nordic Capital in a deal valued at $4.1 billion in 2008. Release

> Lightlake Therapeutics appointed Kevin Pollack as CFO. Pollack has served on the company's board of directors since April. Pollack is also a managing director at Paragon Capital. Release

Medical Devices

After less than two years on the job, Namal Nawana resigned as president of DePuy Synthes Spine to pursue opportunities outside Johnson & Johnson ($JNJ), Mass Device reports. Nawana took the position in March 2011 after serving J&J and the DePuy Family of Companies for 13 years in roles in engineering, marketing, sales and general management. Worldwide Marketing Vice President Max Reinhardt will succeed Nawana as president. The division blended DePuy with Synthes after J&J's $21.3 billion acquisition closed earlier this year. Story

> Endosense called upon Nicolas Marsault to serve as CFO. Marsault most recently worked at Merck Serono. Release

> EOS Imaging named Michael J. Dormer chairman of the board of directors. Dormer served as head of Johnson & Johnson Medical Devices and Diagnostics. Release


Johnson & Johnson's ($JNJ) board of directors elected Alex Gorsky as chairman. Gorksy replaces Bill Weldon, snagging the spot after landing the CEO position in April. Weldon is retiring from J&J after four decades. The transfer of power will take place at the end of this month. Gorsky took over as CEO in April, but Weldon stuck around for awhile to let his successor adjust to his surroundings. Story

> Merck ($MRK) announced that Constantin Fest will head up its investor relations department as of Jan. 1. He will succeed Joshua Young. Fest joined the company's investor relations department in June. He previously worked in investor relations and for the treasury at Lanxess. More

> Savient Pharmaceuticals' ($SVNT) board of directors tapped Robert G. Savage to serve as a member. Savage is now president and CEO of Strategic Imagery. Release

Pharma Manufacturing

> Amerisource Bergen ($ABC) appointed Peyton R. Howell as senior vice president of Amerisource Bergen Corp. and president of global sourcing and manufacturer relations. Howell served as senior vice president of business development of Amerisource Bergen Corp. and president of Amerisource Bergen Consulting Services, a business division of the company. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.